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Simple Summary: With a five-year survival rate of only 3% for the majority of patients, pancreatic
cancer is a global healthcare challenge. Radiomics and deep learning, two novel quantitative imaging
methods that treat medical images as minable data instead of just pictures, have shown promise in
advancing personalized management of pancreatic cancer through diagnosing precursor diseases,
early detection, accurate diagnosis, and treatment personalization. Radiomics and deep learning
methods aim to collect hidden information in medical images that is missed by conventional radiology
practices through expanding the data search and comparing information across different patients.
Both methods have been studied and applied in pancreatic cancer. In this review, we focus on the
current progress of these two methods in pancreatic cancer and provide a comprehensive narrative
review on the topic. With better regulation, enhanced workflow, and larger prospective patient
datasets, radiomics and deep learning methods could show real hope in the battle against pancreatic
cancer through personalized precision medicine.
Abstract: As the most lethal major cancer, pancreatic cancer is a global healthcare challenge. Personalized medicine utilizing cutting-edge multi-omics data holds potential for major breakthroughs in
tackling this critical problem. Radiomics and deep learning, two trendy quantitative imaging methods
that take advantage of data science and modern medical imaging, have shown increasing promise in
advancing the precision management of pancreatic cancer via diagnosing of precursor diseases, early
detection, accurate diagnosis, and treatment personalization and optimization. Radiomics employs
manually-crafted features, while deep learning applies computer-generated automatic features. These
two methods aim to mine hidden information in medical images that is missed by conventional
radiology and gain insights by systematically comparing the quantitative image information across
different patients in order to characterize unique imaging phenotypes. Both methods have been
studied and applied in various pancreatic cancer clinical applications. In this review, we begin with
an introduction to the clinical problems and the technology. After providing technical overviews of
the two methods, this review focuses on the current progress of clinical applications in precancerous
lesion diagnosis, pancreatic cancer detection and diagnosis, prognosis prediction, treatment stratification, and radiogenomics. The limitations of current studies and methods are discussed, along
with future directions. With better standardization and optimization of the workflow from image
acquisition to analysis and with larger and especially prospective high-quality datasets, radiomics
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and deep learning methods could show real hope in the battle against pancreatic cancer through big
data-based high-precision personalization.
Keywords: radiomics; quantitative imaging; pancreatic cancer; machine learning; deep learning

1. Introduction
Pancreatic cancer remains an unsolved global healthcare problem, has the highest mortality rate of all major cancers, and is expected to take the lives of more than 49,830 people
in the US in 2022 alone [1]. While the five-year survival rate has risen considerably for
many other cancers over the past century, it has remained rather stagnant for pancreatic
cancer despite intense healthcare efforts, staying in the single digits for decades and only
recently rising to 10.8% [1]. By the time of diagnosis over half of pancreatic cancers are
metastasized, and for these patients the five-year survival rate is only 3% [1]. The dire
disease situation reflects our inability to diagnose pancreatic cancer early and to effectively
treat it. Our failure to diagnose the disease early results in part from the inaccessibility
of the organ, difficulties in detecting small pancreatic lesions by conventional imaging
approaches, and a poor understanding of the spectrum of heterogeneity in pancreatic cancer. The extremely high degree of heterogeneity in this disease underscores the challenge
of effectively treating any given patient while balancing tumoricidal effects and normal
tissue toxicity. Personalized medicine has hence been proposed for this most fatal cancer
through a systems approach that integrates multi-omics data to tailor medical treatment to
the individual characteristics of each patient.
Despite its high death rate, pancreatic cancer has long been considered unsuitable for
screening programs [2]. Major reasons for this include the absence of clinical symptoms
in the early stage, the variable risks of malignant transformation associated with different
precancerous pancreatic diseases and the difficulties in clinical and imaging-based differential diagnosis, the rare incidence of malignant diseases, and the high risk of pancreatic
biopsy and surgery [3]. Similarly, the same challenges remain in the differential diagnosis
of pancreatic cancer versus benign diseases as well as among different types of pancreatic
cancer. Furthermore, reliable biomarkers are lacking to effectively stratify patients based on
prognosis risk and predicted treatment response. Together with pancreatic cancer remaining the most fatal cancer and screening programs being not widely used, research on early
detection, diagnosis, risk stratification, prognosis prediction, and treatment optimization
remains necessary in order to move towards personalized medicine in pancreatic cancer.
Medical imaging plays an important role in all these crucial effort directions. Various
imaging modalities are already routinely used for cancer screening, detection and diagnosis,
treatment planning, and long-term follow up. Due to the inaccessibility of the tumor and the
risks associated with invasive procedures, pancreatic cancer is especially reliant on imaging.
Moreover, imaging is naturally poised to assess disease heterogeneity and progression,
two important traits of pancreatic cancer. Quantitative imaging, a recently new area of
study based on medical imaging, helps to solve these problems. By approaching images as
data able to be mined, instead of merely pictures in conventional radiology, quantitative
imaging allows for further information to be extracted from medical images as well as for
global assessments across large patient populations. Therefore, these new quantitative
approaches hold the promise of detecting pancreatic cancer characteristics that the naked
eye alone cannot perceive from conventional medical imaging, opening new doors for
personalized medicine in pancreatic cancer.
To date, two main types of quantitative imaging approaches have been researched
for all kinds of medical problems: radiomics and deep learning. Radiomics involves
extraction of hand-crafted features (such as shape, intensity, texture, and wavelet) from
imaging, usually based on segmented regions of interest [4]. Deep learning is a subfield
of machine learning involving algorithms inspired by the structure and function of the
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brain or neural networks [5]. While it can be used as an analysis method for any type of
data, including radiomics, in the narrow sense referred to in this paper deep learning refers
to the application of deep learning methods directly on unsegmented images or image
patches. Figure 1 provides a schematic illustration to contrast the two approaches. While
both approaches take advantage of computational methods to decipher encoded highdimensional information from medical images that is conventionally unfathomable, they
each have their strengths and challenges. Newer studies sometimes combine radiomics
and deep learning approaches, thereby yielding superior results.

Figure 1. A schematic drawing comparing the radiomics approach and the deep learning approach,
using an example case of tumor detection.

This review provides a systematic review of radiomics and deep learning applications
pertaining to pancreatic cancer. The literature search was conducted using the PubMed
(https://pubmed.ncbi.nlm.nih.gov/, accessed on 8 July 2021) and ScienceDirect databases
(https://www.sciencedirect.com/, accessed on 8 July 2021). The keywords “pancreatic
cancer”, “pancreas”, “radiomics”, “imaging”, “machine learning”, and “deep learning”
were used to filter relevant full articles for reference for studies published until November
2021 at the writing of this review. While there have been several reviews of pancreatic
radiomics and machine learning, existing reviews have focused on either the history of
the field, certain biological perspectives, or a specific method or application. Therefore,
this paper hopes to fill a gap by providing a comprehensive review of pancreatic cancer
radiomics and deep learning from both the clinical and the technical perspective in order
to be of use to medical professionals as well as relevant researchers.
2. Technical Overview: Quantitative Imaging and Two Analytical Approaches
As with other types of pictures in our everyday life, medical images have undergone
an analog-to-digital evolution during the past decades. New imaging modalities have been
invented, and visualization of living systems has expanded from two-dimensional (2D
images such as X-rays) to 3D (computed tomography or CT) and 4D (using time as the
fourth dimension to image cyclic motion) as well as from mere anatomy to physiology (such
as positron emission tomography, or PET, and functional magnetic resonance imaging,
MRI). With technological advancements and new modalities has come a growing ability
to generate medical images with far greater detail, accuracy, and precision. It is on these
foundations, the medical community began to perceive medical images as quantitative and
minable data rather than merely as pictures. New approaches aim to automatically generate
quantitative knowledge that is often qualitative/descriptive and manual from conventional
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radiology and to exploit the expanded depth and breadth of information embedded within
advanced medical images which cannot be discovered by the naked eye. In addition to
the visualization they provide, medical images can enable quantitative analyses, much
like other laboratory tests, with valuable information connected both to molecular-level
biological phenotypes and macroscopic clinical presentations. Advantageously, these new
approaches harness data from medical imaging already produced in the clinical workflow, providing a cost-effective yet powerful data source. Moreover, as these quantitative
approaches are based on medical imaging, they are perfect for globally assessing the
heterogeneity of a disease as well as longitudinally monitoring disease progression.
Quantitative medical image analysis usually takes one of two approaches, as illustrated in Figure 1. Extracting handcrafted features from images is the radiomics approach,
and usually involves segmenting a region of interest (ROI) and calculating hundreds to
thousands of predefined mathematical constructs, called radiomic features [6]. The radiomics workflow typically consists of several steps: image acquisition, ROI segmentation,
feature extraction, and model building [6]. The second approach, deep learning, refers
herein to those artificial intelligent methods that implicitly analyze medical images and
hence do not rely on the initial expert inputs of ROI segmentation and handcrafted features.
It should be pointed out that in this paper we address other types of machine learning methods, such as reinforcement learning, in the deep learning category; this distinction is based
on the common definition of learning from the image instead of from extracted features.
Sometimes, the two approaches can be combined to create “fusion” models. When
employed, such fusion models often outperform single-method approaches. Figure 2
plots a histogram of pancreatic cancer-related papers using these quantitative imaging
approaches that have been published in different years. A growing trend can be seen,
especially during the most recent several years.

Figure 2. Quantitative imaging studies using radiomics and deep learning methods in pancreatic
cancer-related research by year of publication.

2.1. Technical Basis: Radiomics
The term radiomics was coined from other “omics” terms such as genomics and
proteomics by combining the words “radiology” and “omics”. Simply put, radiomics is the
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branch of high-throughput data mining research in radiology that involves extracting an
array of hand-crafted quantitative features from medical images. As mentioned above, a
typical radiomics workflow consists of several basic steps, which are depicted in Figure 3.

Figure 3. In a typical radiomics workflow, medical images are acquired and curated and volumes
of interest (VOIs) such as pancreatic tumors are segmented (A). From the segmented VOI images,
hundreds to thousands of radiomic features are then be extracted (B). After conducting preliminary
radiomics analysis such as feature selection (C) and possibly adding clinical and biological information (C1), all features can be integrated through advanced statistical and/or machine learning
methods to develop predictive models (D). The model accuracy and robustness can then be evaluated
on validation and testing datasets (E).

For pancreatic cancer, typical image modalities include those used in clinical management of pancreatic diseases such as CT, MRI, PET, and endoscopic ultrasound (EUS).
Among these, CT is the most widely used imaging modality for pancreatic cancer owing
to its high spatial and temporal resolution, benchmarking sensitivity, and specificity in
pancreatic diseases, as well as its lower cost and wider availability compared with MRI
and PET. A bi-phase or tri-phase pancreatic protocol is usually used with an iodinated
contrast agent for CT image acquisition. With its good soft tissue contrast, MRI is increasingly used to complement CT for pancreatic cancer diagnosis and management. MR
cholangiopancreatography is used as a non-invasive alternative to endoscopic retrograde
cholangiopancreatography. PET commonly uses fluorine 18-fluorodeoxyglucose (FDG), a
glucose analogue, to image high-metabolic cancer. Other tracers can be employed in PET
to image other biological information. PET has been used for pancreatic cancer diagnosis
as well as post-therapy monitoring. Ultrasound is most often used in the EUS setting to
visualize the pancreas from the duodenum or stomach and detect small focal lesions, as
well as to guide biopsies.
While radiomics studies are most often conducted using one of the above-mentioned
imaging modalities, they can combine two or more modalities to provide complementary
and more comprehensive information. From the obtained image, one or more ROIs are
delineated or segmented to allow subsequent analysis to focus on the ROIs. For pancreatic
cancer-based radiomics the ROI is usually the pancreatic tumor, or occasionally metastatic
pancreatic cancer lesions. For pancreatic cancer detection, the ROI can be the entire pancreas or sub-regions thought to potentially contain the cancer. Segmentation can be carried
out either manually, semi-automatically, or automatically. Automatic segmentation is
desirable because it automates a labor-intensive step and is therefore an essential factor for
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securing the large amount of data required for high-quality quantitative imaging studies.
Numerous computer algorithms have been developed for automatic segmentation, from
simple thresholding to atlas-based methods and artificial intelligence-based algorithms.
Human interactions, such as setting the algorithm’s start point, may be required, making it a semi-automatic process. Automatic and semi-automatic segmentation methods
are known to save labor and improve workflow efficiency and interpatient segmentation
consistency [7]. However, when compared with most other types of cancers pancreatic
tumor and pancreas anatomical segmentation can be quite difficult due to the lack of
contrast in boundaries and due to heterogeneity both within the ROIs and in the background. Therefore, automatic/semi-automatic segmentation methods for pancreatic cancer
are an active area of research and development, and manual segmentation remains the
mainstay in pancreatic cancer radiomics [7]. The only exception is in PET-based studies,
where automatic segmentation can be employed based on the thresholding of standardized
uptake values (SUVs). It is worth noting that despite the longer time required to delineate
pancreatic tumors compared to other cancers such as lung tumors, manual segmentation
of pancreatic cancer suffers higher interobserver variabilities as well [8,9]; this can lead
to higher segmentation uncertainties which are then propagated through the radiomics
workflow. To somewhat mitigate this, studies have used multiple observers to enhance the
robustness of manual segmentation; however, there is no standard practice regarding this.
Existing studies showed largely varying degrees of attention to segmentation, with several
taking into consideration inter- and intra-observer reproducibility, others using a single
observer, and others reporting no details about segmentation.
Radiomic features are mathematically defined quantities computed from an image
ROI. They can be divided into different categories, such as intensity, shape, texture, and
higher-order features [6]. Intensity features are sometimes called first-order statistical
features. They are histogram-based quantities such as minimum, mean, median, and
maximum. Other examples include skewness, which reports the asymmetry of the intensity distribution, kurtosis, which reports the “tailedness” versus the flatness of the
distribution, and others. Shape features help to identify ROI shape and size. In addition to
the volume and maximum diameter often used in conventional radiology, shape features
include various others used to quantitatively describe the ROI shape, such as sphericity,
convexity, and irregularity. Texture features are usually second-order statistical features that
can be calculated from various matrices depicting the inter-voxel statistical relationships
between neighboring voxels. The most common texture matrices include the gray-level
co-occurrence matrix (GLCM) that calculates the incidence of voxels with the same intensities at a specific distance along a specific direction and the gray-level run-length matrix
(GLRLM), which calculates the number of consecutive voxels with the same intensity along
a specific direction, as well as others. The texture features are especially useful for quantifying tumor heterogeneity, which is often missed or ambiguous in conventional radiology.
While the above categories of radiomic features can be calculated from the original image,
they can be calculated from the derived image as well after applying image filters or mathematical transformations to the original image. The latter are called higher-order features.
The filters used to extract higher-order features are usually those used in typical image
processing, serving a particular purpose such as highlighting details and suppressing noise.
Common filters used in radiomics include wavelet, Laplacian of Gaussian, and more. With
different image filters and filter parameter settings, the number of radiomic features can
quickly go from a few dozens or hundreds to several thousand. It is worth noting that
unlike intensity and texture features, shape features are invariant with image filters.
For radiomics modeling, the process usually involves feature selection as well as
model development and validation. Because radiomics models are developed from a pool
of hundreds to thousands of radiomic features (which are redundant) and the number
of subjects is usually on the order of a few dozens to a few hundreds, model overfitting
can become a major issue without an effective and robust feature selection or dimension
reduction process. Overfitting tends to happen when a large number of features are
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used to model a dataset of limited size in which the model learns more from the noise
in the dataset than from the signal, leading to a poor fit with new datasets. Various
statistical and machine learning methods are used for radiomics dimension reduction,
including minimum redundancy and maximum relevancy (mRMR), mutual information
maximization, least absolute shrinkage and selection operator (LASSO), and random
forest [5,6]. Through dimension reduction and feature selection a much smaller number
of most relevant radiomic features can be selected, usually under a dozen. When a few
radiomic features are determined to be the most significant and useful for the prediction
in question, they are often called a radiomic signature. Radiomic signatures are used
for model development with both simple statistical and more complex machine learning
methods. A Cox model is one example of a statistical model that is frequently used, simple,
and robust [10]. Other common methods include naïve Bayesian, support vector machine,
neural network, random forest, and more [10]. If the predicted outcome is discrete, and
especially if it is dichotomic (i.e., positive vs. negative), a classification model is built,
whereas if it is continuous, a regression model is used. To develop a more robust and
generalizable radiomic model, proper model validation and testing is often necessary. A
good way to do this is to divide the dataset into a training dataset for training the model
and tuning model parameters and a validation dataset for confirming model validity; one
or more external independent datasets can then be used for model testing to further confirm
the validity and the generalizability of the developed model. Datasets for pancreatic cancer
are often more limited than other types of cancers due to the relative rarity and rapid
progression of the disease. Where external datasets or large dataset sizes are lacking,
methods such as cross-validation and bootstrapping have been used to maximize data
usage and mitigate overfitting [6].
2.2. Technical Basis: Deep Learning
Machine learning is an important branch of artificial intelligence and a powerful
alternative to statistical methods for data analysis and model building. Unlike statistical modeling, which relies on theories, or conventional computer science, which relies
on explicit programming, machine learning involves computers learning from data and
performing tasks such as model building without being explicitly programmed to. Conventional computer algorithms often rely on explicitly programmed “if–then” logics, while
machine learning learns from data without rules-based programming. Traditional machine
learning algorithms use rather simple structures such as linear regression and decision
trees [10]. In contrast, deep learning, a branch of machine learning that takes this a step
further and completely removes the human component, uses more complex algorithms
inspired by the structure and function of human brains [11]. These algorithms are often
called “neural networks” because they mimic the structure and information relay between
neurons in a human brain, and different types of neural networks differ in how information
flows through individual “neuron” layers [11]. In the case of quantitative imaging for
personalized pancreatic cancer, neural networks all have an input, the pancreas image,
and an output, the image-based prediction. The prediction can be a classification problem,
such as whether a lesion is benign or malignant or, what histology a lesion belongs to, or a
regression problem, such as predicting the expected survival time of a patient. As described
in the above section, machine learning or even deep learning approaches can be applied to
analyze radiomics data; the key difference between radiomics and deep learning is that
deep learning as referred to in this review takes the image as its direct input. In contrast,
feature extraction takes place first in radiomics, and the inputs for subsequent data analysis
are these handcrafted imaging features.
The convolutional neural network (CNN) is currently the most commonly used deep
learning method for medical imaging-based studies [10]. Deep learning algorithms automate the process of feature extraction by inherently learning the important features and
applying them to map the input to the output. In a classical artificial neural network (ANN),
this is realized by processing the input through hidden layers which learn the weights of
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different nodes (neurons) and apply appropriate activation functions to yield nonlinearity
for learning the complex relationship between the input and output. There are several challenges using ANNs for image-based deep learning problems. Because the 2D or 3D image
in ANNs is first converted to a 1D vector, the number of nodes drastically scales up with the
image size, making it very computationally expensive. In addition, the spatial information
in the input image is lost in this linear conversion. In contrast, CNNs apply filters (called
“kernels”, hence the term “convolution” in CNN) to flow the information rather than the
1D conversion used in ANNs. For each layer of kernel convolution, there is a subsequent
activation step to introduce nonlinearity into the network and a pooling step to reduce the
dimensionality of the feature map while preserving critical feature information. CNNs
are therefore well-suited for image-based deep learning because of their ability to capture
spatial features from an image and extract relevant features at a low computational cost.
Similar to the radiomics workflow, a good deep learning study will be designed
to have a training dataset, validation dataset, and test dataset. An advantage of deep
learning over radiomics is that it no longer requires the ROI segmentation step. This
saves substantial time and effort requirements, as segmentation is a labor-intensive step of
radiomics, and avoids propagation of segmentation uncertainty into the downstream steps.
Due to the complex image intensity both within the pancreas and in its background, this is
especially important. On the other hand, without using domain-guided ROI or handcrafted
features, the dataset size required to train a robust deep learning model is higher than for
a radiomics study. In medical studies, the dataset size is usually limited; for pancreatic
cancer this is even more of an issue, because rapid disease progression and typically poor
outcomes further limit available data. A few different approaches are used in deep learning
to mitigate the data size issue. CT, MRI, and PET images of the pancreas are 3D images;
however, 2D image slices or even “patches” of 2D slices (subsections of the 2D image) are
usually used as the network inputs instead of the 3D images. As each 3D image set can yield
dozens to hundreds of 2D images and hundreds to thousands of 2D image patches, the data
size increases dramatically, and even the much smaller image or patch drastically reduces
the trainable parameters of the network. Currently, 2D CNNs are the method of choice
for CNN-based deep learning approaches for pancreatic cancer. On the other hand, this
approach may miss the potentially relevant 3D spatial context, which on occasion motivates
investigators to employ a 3D or a 2.5D CNN architecture. Another important method for
mitigating data size limitations for deep learning is data augmentation, in which operations
such as flipping, rotation, translation, and scaling are used to synthesize modified data
from the original data in order to increase the training dataset size. Another method is
transfer learning, where standard architectures designed based on natural images with
pretrained weights, such as ImageNet, are fine-tuned with specific medical images [12,13].
Despite making a certain intuitive sense, methods such as data augmentation and transfer
learning may not always improve deep learning model performance.
3. Clinical Applications
3.1. Pre-Cancerous Pancreatic Lesion Diagnosis
The extreme aggressiveness of pancreatic cancer greatly dampens survival probability when the cancer is diagnosed in late stages, with a five-year survival rate of 3% for
metastatic disease [2]. Unfortunately, pancreatic cancer is usually not detected until the
late stages, with metastatic pancreatic cancer counting for about 52% of patients [14]. In
contrast, while early-stage resectable pancreatic cancer has a much better five-year survival
rate of 39%, only 11% of patients are detected at this stage [15]. Early detection of pancreatic cancer is highly valuable in improving pancreatic cancer survival; however, early
detection is challenging, as there are no validated screening tests available for pancreatic
cancer. Current efforts focus on risk stratification based on intraductal papillary mucinous
neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanIN) as well as familial
risk factors [16]. Pancreatic lesions that are unlikely to progress to cancer may not be
good candidates for surgical resection, as the operation is highly risky, while precancerous
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lesions may, as their prognosis is worse. Because of the potential toxicity and mortality
associated with invasive biopsy of the pancreas, screening and early detection relies heavily
on medical imaging. However, the small size of the early lesions/precursors and complex
radiological appearances of these lesions and their background structures substantially
challenge conventional radiology in providing reliable image-based early detection and
diagnosis of precursor lesions. This offers a window of opportunity for novel quantitative
imaging approaches. Both radiomics and deep learning methods have been applied in
these types of applications.
As listed in Table 1, a series of papers were identified applying radiomics in pancreatic
precancerous lesion diagnosis. As discussed in the introduction, manual segmentation
was used in most of these studies. In the table, we list the number of observers, and for
automatic and semi-automatic segmentation the software or algorithm used to automate
the segmentation. Readers are referred to the original publications for additional details
on segmentation. Standard-of-care imaging modalities (primarily CT) were used in these
studies, though other modalities such as PET were used as well. For example, several radiomic models were developed to diagnose and evaluate the malignancy of cysts, showing
improved accuracy compared to conventional radiology [17–30]. Pancreatic cysts have a
fairly common occurrence relative to pancreatic cancer in adults; prevalence increases with
age, and can show up as incidental image findings or on screening images. Because these
cystic lesions are correlated with a wide range of histologic differentiation and malignant
risk, image diagnosis distinguishing among them represents a crucial challenge. The conventional radiological diagnosis of pancreatic cysts is only accurate 60–70% of the time [31].
Using quantitative approaches, studies have been able to create a radiomics-based model
in order to differentiate cyst types and propose risk stratification useful in determining
treatment. High-risk lesions are recommended as candidates for surgical resection, while
low-risk lesions are recommended as candidates for less aggressive management. For
example, Wei et al. retrospectively studied CT-based radiomics on 260 patients with pancreatic cystic neoplasm and who underwent a pancreatic resection for it [20]. Using the
pathology-established diagnosis of these 260 lesions, the authors grouped them into benign
serous cystic neoplasms (SCNs) and malignant non-SCNs, the latter consisting of IMPNs,
mucinous cystic neoplasms, and solid pseudopapillary neoplasms. With cross-validation in
the training cohort of 200 patients, their radiomic model achieved an area under the receiver
operating characteristic curve (AUC) of 0.84 on the independent validation of 60 patients.
In contrast, only 30% (31 of 102) of the SCNs were correctly diagnosed pre-surgery with
conventional radiology; thus, radiomics clearly shows potential as a computer-aided diagnosis (CAD) tool for improving the efficiency and accuracy of pancreatic cyst diagnosis. In
another study using 53 patients with surgically resected IPMNs, Hanania et al. showed that
a radiomic model based on texture features could differentiate low-grade versus high-grade
IPMNs for the risk stratification necessary in clinical workflows and treatment decisions,
with a high AUC of 0.96 in cross-validation compared with a false positive rate of 36%
using the clinical Fukuoka criteria [17]. Huang et al. were able to use a radiomic model
to predict invasive behavior in pancreatic solid pseudopapillary neoplasms [32]. Song
et al. used a radiomic model to predict the recurrence risk of pancreatic neuroendocrine
neoplasms [33]. Watson et al. applied a deep learning model to predict the malignancy of
pancreatic cystic neoplasms [34]. Surgery is the only treatment for these neoplasms, and
using radiomic and deep learning models can help to predict the prognosis and therefore
led to a more accurate clinical decision regarding surgical resection. The current progress
on texture analysis of pancreatic lesions for differential diagnosis has been reported in a
recent review by Awe et al. [35].
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Table 1. Radiomics studies in diagnosing precancerous pancreatic diseases.

Reference

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

Attiyeh
et al. [36]

CT

In-house
software in
MATLAB

BD-IPMN risk

manual (1)

103 (10-fold
crossvalidation)

CT

In-house
software in
MATLAB

manual (1)

103 (10-fold
crossvalidation)

Chakraborty
et al. [22]

Cheng
et al. [29]

CT and
MRI

ITK-SNAP
software and
Artificial
Intelligence Kit
software

BD-IPMN risk

predicting the
malignant
potential of
intraductal
papillary
mucinous
neoplasms
(IPMNs)

manual (2)

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

255

AUC = 0.79 for
radiomics + clinical
model vs. AUC = 0.67
for clinical model.

150

AUC = 0.77 for
radiomics model and
AUC = 0.81 for
combined radiomics
and clinical model.

1037

MRI radiomics models
achieved improved
AUCs (0.879 with LR
and 0.940 with SVM,
respectively), than that
of CT radiomics
models (0.811 with LR
and 0.864 with SVM,
respectively). All
radiomics models
provided better
predictive performance
than the clinical and
imaging model
(AUC = 0.764).

328

Radiomics model:
AUC = 0.836 (training);
AUC = 0.811
(validation1);
AUC = 0.822
(validation 2).
Radiomics + clinical
model: AUC = 0.903
(training); AUC = 0.884
(validation1);
AUC = 0.876
(validation 2).

60

MRI

MITK software

Low vs.
high-grade in
BD-IPMNs

D‘Onofrio
et al. [30]

MRI

MevisLasb and
MATLAB

Identification
and
classification of
IPMNs

manual (1)

91

<20

Entropy of the ADC
map was found to
correlate with tumor
dysplasia (p = 0.034,
AUC = 0.729)

Hanania
et al. [17]

CT

IBEX

High-grade vs.
low-grade
IPMNs

Manual (2)

53

360

Best univariate
AUC = 0.82

Cui et al.
[26]

manual (2)

103 + 48/51
(validation1/validation2)

Harrington
et al. [23]

CT

In-house
software in
MATLAB

IPMN risk

manual (1)

33

<20

AUC = 0.74 (cyst fluid
inflammatory markers
model) vs. AUC = 0.83
(radiomics model) vs.
AUC = 0.91
(tumor-associated
neutrophils model)

Huang
et al. (2021)
[32]

CT

Pyradiomics

Invasiveness of
SPN

Manual (2)

85

1316

Best AUC = 0.914 on
3D-arterial model
(compared vs. 2D
and venous)
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Table 1. Cont.

Reference

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

Polk et al. [28]

CT

Healthmyne

Malignancy of
IPMNs

semiautomatic (1,
Healthmyne
software)

51 (5-fold crossvalidation)

39

AUC = 0.87 (arterial model)
vs. AUC = 0.83 (venous
model) vs. AUC = 0.90
(combined)

Tobaly et al.
[18]

CT

Pyradiomics

Differentiating
IPMN grades

Manual (1)

296 + 112

107

AUC = 0.84 in training set
and AUC = 0.71 in
validation

Wei et al. [20]

CT

unknown

Computeraided
diagnosis of
SCN

Manual (2)

200 + 60

385

AUC = 0.767 in training
and AUC = 0.837 in
validation

Xie et al. [21]

CT

In-house
algorithm in
MATLAB

Differentiating
MCN vs.
MaSCA

Manual (1)

57

1942

AUC = 0.989 (radiomics
model) vs. AUC = 0.775
(radiological model) vs.
AUC = 0.994 (combined
model) on bootstrapping

Xie et al. [27]

CT

Pyradiomics

MCN vs.
ASCN

semi-manually
(1, 3D Slicer)

216 (10-fold
crossvalidation)

764

Average AUC = 0.784
(radiomics model) vs. AUC
= 0.734 (clinical model)

unknown

Slice thickness = 2 mm:
AUC = 0.77 in training and
AUC = 0.66 in validation;
Slice thickness = 5 mm:
AUC = 0.72 in training and
AUC = 0.75 in validation

Yang et al. [37]

CT

LifeX

Differentiating
SCA vs. MCA

manual (2)

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

78 (4:1)

Abbreviations used in this table: Atypical Serous Cystadenomas (ASCN), Branch-Ductal Intraductal Papillary
Mucinous Neoplasm (BD-IPMN), Intraductal Papillary Mucinous Neoplasm (IPMN), Macrocystic Serous Cystadenoma (MaSCA), Mucinous Cystadenomas (MCA), Mucinous Cystic Neoplasm (MCN), Neuroendocrine Tumor
(NET), Pancreatic Neuroendocrine Neoplasm (PanNEN), Serous Cystadenomas (SCA), Serous Cystic Neoplasms
(SCN), Solid Pseudopapillary Neoplasm (SPN).

Deep learning models are able to differentiate and risk stratify precancerous pancreatic lesions as well, as summarized in Table 2. Similar to radiomics studies, most of
these studies were based on CT, though other modalities such as MRI and EUS were
studied as well. Several studies adopted CNNs to predict lesion or cyst diagnosis and
malignancy, such as lesion type or grade [37–43]. For example, using the EUS images of
206 patients with IPMNs that were later surgically resected, Kuwahara et al. developed
a CNN model that achieved 94% accuracy for IPMN malignancy diagnosis, compared
with 56% accuracy of human diagnosis [43]. In another study, Corral et al. used CNN to
classify IPMN based on MRI images, and achieved a comparable AUC of 0.78, compared
with 0.76 using the American Gastroenterology Association guidelines and 0.77 using the
Fukuoka criteria [42]. In addition to these studies that used deep learning models alone,
other studies combined deep learning with radiomics by adding radiomic features to the
input channels of the deep learning algorithm, and others created fusion models (ensemble
models) to integrate radiomics-based and deep learning-based predictions. Dmitriev et al.
presented such a study [41]; using CT images of 134 patients with pancreatic cysts consisting of four histopathological types, they trained a radiomics model, a CNN model, and
an ensemble/fusion model to classify the cyst lesion types [41]. On cross-validation, the
radiomics model and the CNN model achieved an overall accuracy of 79.8% and 77.6%,
respectively, while the ensemble/fusion model reached 83.6% [41]. Fusion models outperform radiomic models and deep learning models in these early lesion classification and
malignancy diagnosis applications.
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Table 2. Deep learning studies in diagnosing precancerous pancreatic diseases.

Reference

Image

Software

Endpoints

Sample Size
(Training +
Validation)

Results

Two-step nnU-Net
architecture

Detection of PCL

221 (5-fold cross
validation)

Mean sensitivity = 78.8%
(87.8% for
cysts ≥220 mm3 and
96.2% for lesions in distal
pancreas)

CT

CNN

Classification of 4
types of cysts:
IPMN, MCN, SCA,
SPN

134 (10-fold cross
validation)

Accuracy = 83.6% for the
ensemble classifier
(RF + CNN)

Luo et al. [40]

CT

CNN
(ResNet50)

PNEN grading

93 (8-fold cross
validation) + 19
(independent
testing set)

AUC = 0.81 (validation)
AUC = 0.82 (testing)

Nguon et al. [45]

EUS

CNN using
ResNet50

MCNs vs. SCNs

89 + 20 (holdout
validation)

AUC = 0.88 for the
classification of pancreatic
SCNs and MCNs

Watson et al. [34]

CT

CNN
(LeNet
architecture)

PCN malignancy

18 + 9

AUC = 0.966 in high-risk
lesions

Yang et al. [46]

CT

MMRF-ResNet

MCNs vs. SCNs

110 (80:20 total
images)

AUC = 0.96 for the
classification of pancreatic
SCNs and MCNs

CT

* Fusion model.
In-house software
(manual
segmentation by
two observers, 143
radiomic features)

56 + 18

Better validation
performance on arterial
models with AUC = 0.77
(radiomics/DL fusion
models) and AUC = 0.56
(radiomics model),
compared to venous.

Abel et al. [44]

Dmitriev et al. [41]

Song et al. [33]

CT

panNEN
post-surgical
recurrence risk

Abbreviations used in this table: Convolutional Neural Network (CNN), Intraductal Papillary Mucinous Neoplasm (IPMN), Mucinous Cystic Neoplasm (MCN), Multi-channel-Multiclassifier-Random Forest (MMRF), Pancreatic Cystic Lesion (PCL), Pancreatic Cystic Neoplasm (PCN), Pancreatic Neuroendocrine Neoplasm (PanNEN),
Random Forest (RF), Serous Cystadenomas (SCA), Serous Cystic Neoplasm (SC.N).* Combined both a radiomic
analysis and a machine learning analysis.

3.2. Pancreatic Cancer Detection and Diagnosis
Because reliable pancreatic cancer detection and diagnosis is unattainable based simply
on symptoms and signs, medical imaging plays an essential role. A variety of imaging
modalities can be used, including transabdominal US, CT, ERCP, MRCP, etc. CT is the most
commonly used imaging modality among these, with a reported sensitivity of detection
ranging from mid~70% to high~90% [47]. However, the accuracy of detection and diagnosis
is highly dependent on the radiologist’s experience; misdiagnosis and missed diagnosis
are not uncommon. Therefore, radiomics and deep learning have been explored to aid
the clinical task of image-based pancreatic cancer detection and diagnosis. Tables 3 and 4
summarize radiomics and deep learning research on these applications, respectively.
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Table 3. Radiomics studies in pancreatic cancer detection and diagnosis.

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

CT

In house with
Matlab

Discriminating
histopathologic
characteristics
of PNET

Manual (1)

39

69

Best AUC = 0.86

Bevilacqua
et al. [49]

PET/CT

In house with
Matlab

Grade 1 vs. 2
primary PNET

Manual (1)

25 + 26
(model A)
26 + 25
(model B)
51 (model C)

60

Best performance was
achieved by model A
test AUC = 0.90

Bian et al. [50]

MRI

Pyradiomics

G1 vs. G2/3
grades in
patients with
PNETs

Manual (2)

157

1409

AUC = 0.775

Bian et al. [51]

MRI

Pyradiomics

PNET grades

Manual (1)

97 + 42

3328

AUC = 0.851 (training)
AUC = 0.736
(validation)

Canellas et al.
[52]

CT

TexRAD

Differentiating
PNET grades

Manual (2)

101

36

Accuracy of 79.3% for
differentiating grade1
vs. grades 2/3.

IBEX

Histological
grades of
PDAC

Manual (2)

151 + 150
(local) +100
(external
validation)

1452

AUCs = 0.961
(training), AUC = 0.910
(local validation), and
AUC = 0.770 (external
validation)

Manual (2)

915 + 200
(local test) +
264
(external test)

88

AUC = 0.98 (local test)
AUC = 0.91
(external test)

Manual (3)

255 + 125

478

AUC = 0.999

410

AUCs for the T1WI,
T2WI, A and, P and
clinical models were
0.893, 0.911, 0.958, 0.997
and 0.516 in the
primary cohort, and
0.882, 0.902, 0.920, 0.962
and 0.649 in the
validation cohort.

2376

In validation,
AUC = 0.853 for T2
(best performing single
sequence), AUC = 0.925
for multi-parametric
MRI radiomics model,
and AUC = 0.962 for
radiomics + clinical
model.

Reference

Benedetti et al.
[48]

Chang et al.
[53]

CT

Chen et al. [54]

CT

Pyradiomics

Differentiating
PDAC from
normal
pancreas

Chu et al. [55]

CT

Pyradiomics

Differentiating
PDAC from
normal
pancreas

Deng et al. [56]

Gu et al. [57]

MRI

MRI

IBEX

Artificial
Intelligence Kit

DifferentiatingPDAC
and MFCP
Manual (2)
lesions

SPN vs.
differential
diseases
(PDAC, NET,
and
cystadenoma)

manual (2)

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

64 + 55

48 + 113
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Table 3. Cont.

Reference

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

Li et al. [58]

CT

Fire Voxel

Atypical PNET
vs. PDAC

Manual (2)

75

<20

Best AUC = 0.887

Linning et al.
[59]

CT

In house with
Matlab

PDAC vs.
autoimmune
pancreatitis

Manual (2)

96 (5-fold
cross
validation)

1160

AUC = 0.977

Liu et al. [60]

PET/CT

Pyradiomics

PDAC vs.
autoimmune
pancreatitis

Manual (2)

112 (10-fold
cross
validation)

502

AUC= 0.967

Liu et al. [61]

CT and
MRI

Pyradiomics

PNET grades

Manual (2)

82 + 41

1209

AUC = 0.92 (training)
AUC = 0.85 (validation)

Park et al. [62]

CT

Pyradiomics

PDAC vs.
autoimmune
pancreatitis

Manual (4)

120 + 62

431

AUC = 0.975

Reinert et al.
[63]

CT

Pyradiomics

Differentiating
PDAC from
PanNEN

Manual (1)

95

92

8 features highly
significant (p < 0.005)

CT

Analysis Kit
software

Pancreatic
adenosquamous
carcinoma vs.
PDAC

Manual (1)

112
7:3 ratio

792

Average AUC of 0.82

Ren et al. [64]

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

Song et al. [65]

MRI

Pyradiomics

Differentiating
NF-PNET and
SPN

Manual (2)

79 (7:3 ratio)

396

AUC = 0.978
(radiomics) and
AUC = 0.965
(radiomics + clinical) in
the training set
AUC = 0.907
(radiomics) and
AUC = 0.920
(radiomics + clinical) in
the validation set

Xing et al. [66]

PET/CT

Pyradiomics

Pathological
grades in
PDAC

Manual (2)

99 + 50

about 3000

AUC o = 0.994
(training)
AUC = 0.921
(validation)

Manual (3)

82
3:1 ratio

40

AUC = 0.82 (G1 vs. G2),
0.70 (G2 vs. G3), and
0.85 (G1 vs. G3),
respectively

Manual (2)

59 + 40

585

AUC = 0.968 (training)
AUC= 0.876
(validation)

Zhang et al.
[67]

CT

LifeX

Pathological
grades of
PNETs

Zhao et al. [68]

CT

In house with
Matlab

Grade 1 vs. 2
in PNET

Abbreviations used in this table: Area Under Curve (AUC), Mass-forming Chronic Pancreatitis (MFCP), Pancreatic
Neuroendocrine Neoplasm (PanNEN), Pancreatic Adenocarcinoma (PDAC), Neuroendocrine Tumor (NET) or
Pancreatic Neuroendocrine Tumor (PNET), Solid Pseudopapillary Neoplasm (SPN).
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Table 4. Deep learning studies in pancreatic cancer detection and diagnosis.

Reference

Chu et al. [69]

Liu et al. [70]

Ozkan et al. [71]

Image

Software

Endpoints

Sample Size
(Training +
Validation)

Results

CT

Deeply supervised
nets with
encoder-decoder
architecture

PDAC detection

456

Sensitivity = 94.1%,
specificity = 98.5%

CNN

Differentiating
pancreatic cancer
vs. normal
pancreas

295 + 691 (local test
1 + local test 2 +
external test)

AUC = 0.997 (local test 1)
AUC = 0.999 (local test 2)
AUC = 0.920 (external test)

ANN with Relief-F
feature reduction
method

Pancreatic cancer
diagnosis for
different age
groups

260 + 72

Age groups in years: <40,
40–60, >60:
accuracy = 92%, 88.5%,
91.7%, respectively
all age groups:
accuracy = 87.5%

68 (10-fold cross
validation)

Benign vs. malignant
pancreatic lesions:
AUC = 0.957
Chronic pancreatitis vs.
pancreatic cancer:
AUC = 0.965

CT

EUS

Săftoiu et al. [72]

EUS

ANN (MLP)

Differential
diagnosis of
chronic
pancreatitis and
pancreatic cancer

Săftoiu et al. [73]

EUS

ANN (MLP)

Diagnosis of focal
pancreatic masses

258 (10-fold cross
validation)

Average AUC = 0.94 over
100 runs of a complete
cross-validation cycle

Si et al. [74]

CT

CNN
ResNet18
(pancreas location),
U-Net32 (pancreas
segmentation),
ResNet34
(pancreatic tumor
diagnosis)

Fully automated
diagnosis of
pancreatic tumors

319 + 347

AUC = 0.871 on testing for
detection of all tumor
types

Tonozuka et al. [75]

EUS

CNN

PDAC detection

92 (10-fold cross
validation) + 47

AUC = 0.924 (cross
validation)
AUC = 940 (test)

CT

Faster R-CNN
combined with
Feature Pyramid
Network for
feature extraction

Pancreatic tumor
detection

2650 + 240
(images)

AUC = 0.946

Zhang et al. [76]

Abbreviations used in this table: Artificial Neural Network (ANN), Area Under Curve (AUC), Convolutional
Neural Network (CNN), Multilayer Perceptron (MLP), Pancreatic Adenocarcinoma (PDAC).

For detection, several works have shown the utility of radiomic models in differentiating pancreatic cancer tissue and healthy tissue [54,55]. Chu et al. trained a whole-pancreas
ROI-based radiomic model on 225 training cases and validated the model on 125 validation cases [55]; the resulting model consisted of 40 radiomic features and achieved a very
high AUC of 99.9% [55]. Chen et al. applied radiomic features and machine learning to
investigate the utility of radiomics modeling in detecting pancreatic cancer [54]. Based on
contrast-enhanced CT, they observed that pancreatic cancer tends to be hypodense and
more heterogeneous compared with normal pancreas, as reflected by the relevant radiomic
feature values. Quantitatively, their radiomics model trained on >1000 subjects achieved
AUCs of 0.98 and 0.91 on local and external test datasets.
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Deep learning models have proven useful for detecting pancreatic cancer. Zhang
et al. used a novel deep learning framework consisting of Augmented Feature Pyramid
networks, Self-adaptive Feature Fusion, and a Dependencies Computation Module to
detect pancreatic cancer tumors, which resulted in an AUC of 0.95 on internal testing [77].
In a large-cohort study, Liu et al. applied CNN-based modeling on contrast-enhanced CTs
of ~700 subjects (~1:1 with pancreatic cancer vs. healthy pancreas controls, divided 4:1
into training and validation sets) [70]. The model was further tested on a ~200-subject
independent local cohort and a ~350-subject independent international cohort, achieving
an AUC of 1.00 and 0.92, respectively [70]. For their local validation and testing datasets,
the performance of the CNN model was compared against that of human radiologists and
showed significantly higher sensitivity [70]. In another study, Chu et al. reported their initial
experience of training deep learning networks to detect pancreatic adenocarcinoma [69].
They took a two-step approach to their curated large CT cohort of pancreatic cancer patients
and controls with a healthy pancreas, using supervised learning to first train deep learning
models to automatically segment all abdominal organs, and then to detect pancreatic cancer.
Their algorithms achieved segmentation performances superior to published state-of-theart algorithms, and showed 94.1% sensitivity and 98.5% specificity for pancreatic cancer
detection in preliminary testing.
As pancreatic cancer is highly aggressive, correctly diagnosing it from benign or lessaggressive lesions could reduce unnecessary surgical resections that potentially lead to
patient morbidity. Image-based grading and histopathology prediction can aid better treatment stratification. Reinert et al. identified CT-based textual features that can differentiate
between pancreatic ductal adenocarcinoma and pancreatic neuroendocrine tumors as well
as between low-grade and high-grade pancreatic neuroendocrine tumors [63]. Gu et al.
were able to differentiate pancreatic ductal adenocarcinoma and neuroendocrine tumors
from solid pseudopapillary neoplasm using MRI radiomic features [57]. Zhao et al. and
Benedetti et al. used CT-based radiomic features to discriminate pancreatic neuroendocrine
tumor grades, and Bendetti et al. predicted lymph node invasion status [48,68]. Similarly,
using texture features on CT, Canellas et al. were able to differentiate grade 1 from grade 2
and 3 pancreatic neuroendocrine tumors [52]. In a large-cohort study, Chang et al. used
contrast-enhanced CTs of ~300 patients to train and validate radiomics models to differentiate high-grade versus low-grade pancreatic ductal adenocarcinoma, achieving an AUC
of 0.91 on the internal validation set and 0.77 on a 100-patient external testing cohort [53].
Other imaging modalities have been explored as well; in an early study, Zhu et al. used a
support vector machine model on texture features from EUS images to differentiate pancreatic cancer from chronic pancreatitis [78]. With a total of ~400 patients, >90% accuracy
was achieved in cross-validation. Based on various MRI sequences, Deng et al. tested
radiomics models and compared them against a clinical model to differentiate pancreatic
cancer from mass-forming chronic pancreatitis [56]. The radiomic models developed on
a training cohort achieved performances much superior to the clinical model on a validation cohort from a different institution (AUCs of 0.88–0.96 vs. 0.65). Bevilacqua et al.
used [68Ga]Ga-DOTANOC PET/CT radiomic features to detect grade 1 and 2 pancreatic
neuroendocrine tumors [49].
Deep learning models have been successfully applied in pancreatic cancer diagnosis.
CNN-based models have been frequently used. Si et al. applied ResNet models to diagnose
different pancreatic lesions and achieved an average accuracy of 82.7% for all tumor
types [74], and generated saliency maps to highlight the image regions relevant to the
decision. Saftoiu et al. used an extended neural network analysis on EUS elastography
for differential diagnosis of pancreatic cancer and chronic pancreatitis, and achieved an
average testing performance of 95% on cross-validation [72]. Ziegelmayer et al. applied
CNN modeling on CT images to discriminate between pancreatic cancer and autoimmune
pancreatitis, and compared it with radiomics modeling [79]. On cross-validation, they
achieved an average AUC of 0.90 with the deep learning model, outperforming their
radiomic model, which had an AUC of 0.80.
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Correctly detecting and diagnosing pancreatic cancer is crucial for managing the
disease and selecting optimal treatment, and is ultimately crucial for patient outcomes.
Accurate diagnosis of non-cancer versus cancer could reduce unnecessary surgical resections, which can lead to patient morbidity. Overall, both radiomic and deep learning
models show great promise in these clinical tasks and could be implemented into computeraided diagnosis systems for pancreatic cancer. These models could reduce the time and
manual effort involved in these clinical tasks, reduce invasive biopsy procedures, and
potentially offer more accurate diagnoses in order to improve treatment planning and
improve patient outcomes.
3.3. Pancreatic Cancer Prognosis
Significant radiomic and deep learning features in pretreatment images have been
used to predict treatment efficacy for pancreatic cancer. Survival can be predicted by both
radiomic and deep learning models using pretreatment images in order to determine the
level of treatment needed for the best chance of patient survival. Similarly, predictions
on recurrence, metastasis, and surgical margins can be used to strategize regarding the
optimal treatment for an individual patient.
Radiomic models have been used to predict progression-free survival, relapse-free
survival, and overall survival for pancreatic cancer [80–94], and deep learning models have
been used to model survival as well [95–99]. Mapelli et al. used a radiomic model to predict
the aggressiveness of pancreatic neuroendocrine neoplasms [100]. Gao et al. used a deep
learning CNN model to predict grades of PNET, with an average accuracy of 85.1% ± 0.4%
and an average accuracy on the external validation set ranging between 79.1 and 82.4% [99].
Klimov et al. were able to predict metastasis risk in PNETs using a deep learning approach
that had high ability to differentiate tumors, with an accuracy of >95% [101]. The models of
both Gao et al. and Klimov et al. show promise in accurately assigning treatment plans to
PNET patients while correctly predicting prognosis. Tang et al. were able to predict early
recurrence in resectable pancreatic cancer using a radiomic nomogram [102]. Patients with a
high risk of recurrence may be treated more aggressively or with other treatment modalities
using the risk stratification proposed by the model developed by Tang et al. Bian et al.
predicted the risk of lymph node metastasis in pancreatic cancer patients using a radiomic
model [103]. Liu et al. were able to predict lymph node metastasis with their radiomic
model as well [104]. If a pancreatic cancer patient already has lymph node metastases, a
radical pancreatic operation may be futile and not worth the risks. The models developed
by Bian et al. and Liu et al. could help to relieve patients from unnecessary operations.
In a different study, Bian et al. created a radiomic model to predict superior mesenteric
vein resection margin (R1/2 vs. R0) in patients with pancreatic head cancer; their model
was able to predict patient prognosis, as R1/2 resection is associated with poor overall
survival relative to R0 resection [105]. Hui et al. were able to predict resection margin
for pancreatic head cancer using a radiomic model as well [106]. Zhang et al. created a
radiomics model that could predict postoperative pancreatic fistula in patients undergoing
pancreaticoduodenectomy; their model could help with decisionmaking regarding risks
of a pancreaticoduodenectomy [107]. Postoperative pancreatic fistula is one of the more
harmful consequences of a pancreatic resection or pancreaticoduodenectomy, and the use
of any of the aforementioned models could help to predict patient prognosis and assist
with clinical decision making.
Li et al. created a radiomic model that could predict CD8+ tumor-infiltrating lymphocyte expression levels in patients with pancreatic ductal adenocarcinoma [107]. Patients
with high levels of CD8+ tumor-infiltrating lymphocyte expression are possibly able to
undergo immunotherapy targeting immune checkpoint inhibitors to improve their prognosis [108]. Bian et al. were able to predict tumor-infiltrating lymphocyte expression in their
radiomic and deep learning models as well [109]. These kinds of models, which can predict
patient prognosis, lead to better treatment predictions, and ultimately improve the clinical
decisionmaking process, are summarized in Tables 5 and 6.
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Table 5. Radiomics studies in pancreatic cancer prognosis.

Reference

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

Bian et al.
[103]

CT

Pyradiomics

Lymph node
metastasis in
PDAC

Manual (2)

225 (10-fold
cross
validation)

1029

Multivariate p < 0.0001

Bian et al.
[105]

CT

Pyradiomics

R0 vs. R1
margin in
pancreatic
head cancer

Manual (2)

181 (10-fold
cross
validation)

1029

AUC = 0.750

Pyradiomics

Tumorinfiltrating
lymphocytes in
patients with
PDAC

Manual (2)

116 + 40

1409

training AUC = 0.86
and validation sets
AUC = 0.79

CT

TexRAD

Disease-free
survival in
patients with
resectable
PDAC

Manual (1)

99

<20 (texture)

AUC 0.71

CT

Analysis Kit
software

Stage I-II vs.
III-IV PDAC
and predict
overall
survival

Manual (2)

94 + 41

384

Training cohort
AUC = 0.940
Validation cohort
AUC = 0.912

TexRAD

Progressionfree survival
and overall
survival in
patients with
unresectable
PDAC

Manual (1)

41

<20 (texture)

AUC = 0.756

MODDICOM
software

One-year local
control in
patients with
locally
advanced
pancreatic
cancer

Manual (2)

35 (5-fold cross
validation)

368 radiomic
features and
276 delta
features

AUC = 0.78

Bian et al.
[109]

Cassinottoet
al.
[110]

Cen et al.
[84]

Cheng
et al.
[80]

Cusumano
et al.
[83]

D’Onofrio
et al.
[93]

Eilaghi
et al.
[111]

Hang et al.
[89]

MRI

CT

MRI

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

CT

In house with
unknown
software

Metastatic vs.
non-metastatic
PDAC

Manual (1)

288

<20

Significant univariate
features identified: size,
arterial index,
perfusion index, and
permeability index
(p < 0.05).

CT

In house with
Matlab

Overall
survival for
PDAC after
surgical
resection

Semiautomatic (1,
in-house
ProCanVAS)

30

<20

Max AUC = 0.716 in
univariate

LifeX

Overall
survival for
pancreatic
cancer with
liver
metastases

Manual (1)

39

36

Nomogram showed
good discriminative
ability (CI = 0.754).

CT
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Table 5. Cont.

Reference

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

Hui et al.
[106]

CT

Rbio2.8

R0 or R1 margin in
pancreatic head
adenocarcinoma

Manual (2)

86
(leave-one-out
cross
validation)

Pyradiomics

Survival and tumor
subtype in PDAC

Manual (2)

102 (10-fold
nested cross
validation) + 30

1474

AUC = 0.93 in
cross-validation
AUC = 0.90 in
independent validation

CT

Pyradiomics

Prognostic value of
CT-derived
radiomic features
for resectable
PDAC

Manual (2)

30 + 68

410

Validation cohort with
p-value of 0.047

Kim et al.
[85]

CT

In house with
unknown
software

predict prognosis
after curative
resection in
pancreatic cancer

Manual (1)

116

<20 (GLRLM)

One feature with
p = 0.025 for survival

Li et al.
[82]

CT

Pyradiomics

Lymph node
metastasis

Manual (2)

118 + 41

2041

Best AUC = 0.811

Pyradiomics

CD8+
tumor-infiltrating
lymphocyte
expression levels in
patients with
PDAC

1409

Training set
AUC = 0.75 and
validation set
AUC = 0.67

Pyradiomics

Lymph node
metastasis in
resectable PDAC

1124

AUC = 0.841
(radiomics) vs.
AUC = 0.682
(conventional)

Kaissis
et al.
[95]

Khalvati
et al.
[86]

Li et al.
[108]

Liu et al.
[104]

Mapelli
et al.
[100]

Mapelli
et al.
[94]

MRI

CT

CT

PET/CT

Chang-Gung
Image Texture
Analysis
software
package

PET/CT

Chang-Gung
Image Texture
Analysis
software
package

Manual (2)

Manual (2)

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

23

AUC = 0.861

137 + 47

85

PanNEN risks

Automatic
with SUV
thresholding
(40% of
SUVmax)

61

9

Four principal
components extracted:
PC1 correlated with all
18F-FDG variables,
while PC2, PC3 and
PC4 with
68Ga-DOTATOC
variables. PC1 could
predict angioinvasion
(p = 0.0222); PC4 could
predict lymph nodal
involvement
(p = 0.0151). All PCs
except PC4 could
predict tumor
dimension

PanNEN risks

Automatic
with SUV
thresholding
(40% of
SUVmax)

83

9

Individual parameters
evaluated for various
clinical risk endpoints
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Table 5. Cont.

Image

Software

Endpoints

Segmentation
Process
(Number of
Readers)

PET

Spaarc Pipeline
for Automated
Analysis and
Radiomics
Computing
(SPAARC)

Distant-relapsefree-survival after
radiochemotherapy for
locally advanced
pancreatic cancer

Semiautomatic
(gradient
based,
PET-Edge,
MIM)

CT

Pyradiomics

Overall survival
and time to
progression;
validate radiomic
features developed
in resectable PDAC
on a test set of
patients with
unresectable PDAC
undergoing
chemotherapy

CT

ITK-SNAP
software and
Artificial
Intelligent Kit

Survival after
upfront surgery in
patients with
PDAC

MRI

AK software

Toyama
et al.
[87]

Xie et al.
[88]

Reference

Mori et al.
[90]

SalinasMiranda
et al.
[91]

Shi et al.
[112]

Tang et al.
[102]

Zhang
et al.
[107]

Sample Size
(Training +
Validation)

Number of
Features
Extracted

Results

116 + 60

198

Training cohort
p = 0.002 and
validation cohort
p = 0.03.

Manual (1)

0 + 108

2 previously
developed
features

One feature remained
significant with a
HR = 1.27 for overall
survival and a HR of
1.25 for time to
progression

Manual (2)

210 + 89

792

CI = 0.74 in the training
set and CI = 0.73 in the
validation set.

Early recurrence in
resectable
pancreatic cancer

Manual (2)

123 + 54 (+126
external
validation)

328

AUC = 0.871 (training
cohort), AUC = 0.876
(internal validation
cohort), and
AUC = 0.846 (external
validation cohort).

PET

LifeX and
machine
learning
algorithms

1-year survival

Semiautomatic
(2, with SUV
thresholding at
40% of
SUVmax)

161 (10-fold
cross
validation on
138)

42

Best AUC = 0.720

CT

Mazda

Survival in patients
with resected
PDAC

Manual (3)

147 + 73

300

AUC = 0.701 in training
cohort
AUC = 0.715 in
validation cohort

Pyradiomics

Postoperative
pancreatic fistula
after pancreaticoduodenectomy

1219

AUC = 0.825 in training
cohort and
AUC = 0.761 in
validation cohort

CT

Manual (2)

80 + 37

Abbreviations used in this table: Area Under the Receiver Operating Curve (AUC), Concordance Index (CI),
Gray-level Run-length Matrix (GLRLM), and Pancreatic Adenocarcinoma (PDAC).
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Table 6. Deep learning studies in pancreatic cancer prognosis.

Reference

Gao et al.
[99]

Klimov et al.
[101]

Li et al.
[92]

Yao et al.(2020)
[96]

Sample Size
(Training +
Validation)

Results

96 (5-fold cross
validation) + 10

Micro-average
AUC = 0.912 in internal
validation set;
Micro-average
AUC = 0.845 in external
validation set

Metastasis risk in
PNET

89

Tissue annotation: per-tile
accuracy > 95%, whole
slide 79%;
Metastasis prediction:
hazard ratio 4.71

CT

Fusion model (70
conventional
features and 256
deep convolutional
features) Matlab

Survival time
in PDAC

111 (k-fold
leave-one-out cross
validation, k = 10,
20, 30, 40)

Average AUC = 0.90

CT

* Fusion model.
Pyradiomics, CNN
(CEconvLSTM,
combined with
3D-ResNet18 as
the encoder)

PDAC survival
and
surgical margin

205 (5-fold cross
validation)

survival prediction:
C-index = 0.705;
resection margin
prediction:
balanced-accuracy = 0.736

296 (4-fold nested
cross validation)

1-year overall survival:
AUC = 0.684;
2-year overall survival:
AUC = 0.689

Image

Software

MRI

CNN combined
with GAN for
synthetic image
generation

Whole-slide
imaging of
resected tissues

CNN for tissue
annotation, 18
different ML
models for
metastasis
prediction

Endpoints

PNET grades

Yao et al.
[113]

CT

CNN

Survival of
primary resectable
PDAC

Zhang et al.
[97]

CT

CNN-based
transfer learning
model

prognosis of
overall survival in
PDAC patients

68 (5-fold cross
validation) + 30

AUC = 0.72 in
training cohort;
AUC = 0.81 in test cohort

CT

* Fusion model.
Pyradiomics.
Random
forest-based
models trained
from features
extracted using
traditional
radiomics pipeline
and transfer
learning

Overall survival in
PDAC

68 (10-fold cross
validation) + 30

AUC = 0.84 in test cohort

Zhang et al.
[98]

Abbreviations used in this table: Area Under Curve (AUC), Convolutional Neural Network (CNN), Generative Adversarial Network (GAN), Machine Learning (ML), Pancreatic Adenocarcinoma (PDAC), Pancreatic
Neuroendocrine Tumor (PNET).* Combined both a radiomic analysis and a machine learning analysis.

3.4. Treatment Stratification, Delta-Radiomics, and Radiogenomics
Apart from diagnosis and differentiation of pancreatic diseases, radiomics can play
a helpful role in predicting optimal therapy paths. Several studies in radiomics have
predicted treatment response to pancreatic cancer [81,111,114–120]. Parr et al. applied
radiomic models to pretreatment CT images in order to predict overall survival and locoregional recurrence of pancreatic cancer after stereotactic body radiation therapy [81]. Their
radiomic model and the model combining radiomic and clinical features outperformed the

Cancers 2022, 14, 1654

22 of 33

pure clinical model in these predictions, with an average concordance index of 0.66 and
0.68 versus 0.54 for survival and an average AUC of 0.78 and 0.77 vs. 0.66 for recurrence
on validations [81]. Cozzi et al., using a hybrid clinical–radiomics model, were able to
differentiate high and low risk in terms of overall survival for patients treated with stereotactic body radiation therapy, with an AUC of 0.81 [114]. Those patients with a low overall
survival prediction may need more aggressive treatment, and with this model high-risk
and low-risk groups can be more accurately identified. Watson et al. applied deep learning
CNN to predict pathologic tumor response to neoadjuvant therapy in pancreatic cancer,
with an AUC of 0.738 in predicting response to chemotherapy and an accuracy of 78.3% in
predicting response to resectability [121].
Another direction of radiomics, as in studies on other cancers, is delta-radiomics. Deltaradiomics assesses the temporal change or kinetics of radiomic signatures and explores
its value in evaluating tumor progression or predicting long-term patient outcomes. The
examined temporal window using delta-radiomics can be relatively short, such as when
using daily imaging during a radiation therapy treatment course, or more extended, as
when using periodical imaging from diagnosis to treatment and follow-up. Delta-radiomics
has been explored for pancreatic cancer thanks to its value in prognosis prediction and
treatment stratification. Using daily imaging during a radiation therapy treatment course,
Chen et al. showed that patients with good pathological pancreatic tumor response tended
to have large changes in certain radiomic features of the tumor compared to those with
poor tumor response; radiation-induced delta-radiomics may potentially be used for early
assessment of treatment response during radiation delivery [122].
Aside from the above clinical applications, radiomics has been used in radiogenomics.
Radiogenomics is an offshoot branch of radiomics that applies radiomic workflow and
imaging features coupled with genomic profiles [123] to assess the association between
imaging phenotypes and the underlying tumor biology. These radiomic signatures associated with underlying patterns of gene expression can then be used to predict prognosis
and optimal treatment. While radiogenomics has been more widely studied for other types
of cancer, pancreatic cancer radiogenomic studies remain sparse. On the other hand, the
genomic landscape of pancreatic cancer is diverse and many mutations have been detected,
creating many potential opportunities for radiogenomic analysis [36]. A few radiogenomic
studies have been conducted [8,9,36,124,125]. Katabathina et al. suggest that the varied
biological tumor features related to the different mutations in panNENs may result in
morphological changes that are appreciable with imaging [126]. McGovern et al. identified
CT-based radiomic features that are significantly associated with the alternative lengthening of the telomere phenotype of pancreatic neuroendocrine tumors [36]. Attiyeh et al.
demonstrated that radiomic signatures of preoperative CT can predict the mutation status
of certain pancreatic cancer driver genes, such as SMAD4 [36]. The use of radiogenomics
can increase personalized medicine within pancreatic cancer patients, leading to better
outcomes. Table 7 summarizes the applications of both radiomics and deep learning in
treatment stratification, delta-radiomics, and radiogenomics, respectively.
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Table 7. Radiomics and deep learning studies in treatment stratification, delta-radiomics, and
radiogenomics in pancreatic cancer.

Reference

Borhani
et al.
[120]

Image

CT

Parr et al.
[81]

CT

<20

60 + 40

41

AUC = 0.81 for the
training set and
AUC = 0.73 for the
validation set

Manual (1)

Overall survival
after stereotactic
body radiation
therapy

Manual (1)

Pyradiomics

Efficacy of S-1 (oral
antitumor agent)

Semiautomatic
(2, a generic
automatic
segmentation
algorithm
based on a 3D
domain using
a prototype
software,
Radiomics,
Siemens)

31 + 15

110

T1WI_NGTDM_Strength
and tumor location are
independent predictors
of the efficacy of S-1 in
the training cohort
(p = 0.005 and 0.013),
but marginal in the
validation cohort
(p = 0.073 and 0.050).

IBEX

Delta-radiomic
change and overall
progression in
patients undergone
neoadjuvant CRT

Manual (1)

50
(leave-one-out
cross
validation) +
40 (external)

>1300

Best AUC = 0.94

Over 1300

The Cox proportional
multivariate hazard
analysis showed that a
treatment related
decrease in CA19-9
levels (p = 0.031) and
delta radiomics
(p = 0.001) were
predictors of survival.

841

Validation: Average CI
of 0.66 (radiomics) vs.
0.54 (clinical) for
survival; Average AUC
of 0.78 (radiomics) vs.
0.66 (clinical) for
recurrence.

LifeX

CT

20

p = 0.046, 0.058, 0.042,
and 0.12 for MCTN, SD,
skewness and kurtosis,
respectively.

Delta-radiomic
change during CRT
and pathology
responses on 15
patients that
undergone
subsequent
resections

CT

Nasief et al.
[117]

<20 for each
filter, 6 filters
applied

Prognostic features
identified for
histological response
(p < 0.05), biochemical
response (p < 0.01) and
disease-free survival
(p = 0.001).

TexRAD

Cozzi et al.
[114]

CT

Results

Histologic
response to
neoadjuvant CRT
and disease-free
survival in patients
with potentially
resectable PDAC

CT

Nasief et al.
[116]

Number of
Features
Extracted

Endpoints

In house with
Matlab

MRI

Sample Size
(Training +
Validation)

Software

Chen et al.
[122]

Liang et al.
[119]

Segmentation
Process
(Number of
Readers)

IBEX

Delta-radiomic
change and overall
progression in
patients undergone
neoadjuvant CRT

Pyradiomics

Overall survival
and locoregional
recurrence
following
stereotactic body
radiation

Manual (1)

Manual (1)

Manual (2)

39

24

74 (3-fold cross
validation)
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Table 7. Cont.

Reference

Steinacker
et al.
[115]

Watson
et al.
[121]

Zhou et al.
[118]

Image

CT

CT

CT

Software

Endpoints

Semiautomatic
(1,
mintLesion®.)

13

<20

CNN (based
onLeNet
architecture)

Pathologic tumor
response to
neoadjuvant
therapy in
pancreatic
adenocarcinoma

NA (deep
learning)

65 + 16

NA (deep
learning)

AUC = 0.738 (DL),
AUC = 0.564 (CA19-9),
and AUC = 0.785
(combined)

In house with
Matlab

Candidate
selection for
irradiation stent
placement among
patients with
unresectable
pancreatic cancer
with malignant
biliary obstruction

Manual (2)

74 + 32

620

CI = 0.791
(radiomics + clinical)
vs. CI = 0.673 (clinical)
in the training set;
CI = 0.779
(radiomics + clinical)
vs. CI = 0.667 (clinical)
in the validation
groups

Manual (1)

35

255

Radiomics associated
with SMAD4 status
and the number of
genes altered

Manual (2)

57

558 2D and 994
3D features

AUC = 0.96

1037

Radiogenomicspredicted p53
mutations associated
with poor prognosis
(p = 0.02), whereas the
predicted abnormal
expression of PD-L1
was not
significant (p = 0.10).

35

Features identified that
associated with KRAS
and SMAD4 gene
mutations, but not with
TP53 and
CDKN2A gene
mutations.

<20

Univariate (p < 0.05)
and multivariate
features (p = 0.006)
found.

Matlab

Gao et al.
[125]

MRI

Pyradiomics

TP53 mutation
status

McGovern
et al.
[124]

PET

CT

Results

MintLesion

CT

Lim et al.
[8]

Number of
Features
Extracted

Overall
progression in
advanced
pancreatic cancer
treated with
systemic therapy

Attiyeh
et al.
[36]

CT

Sample Size
(Training +
Validation)

Two significant
univariate features
identified: mean
positivity of pixel
values (p = 0.030 for
progression); kurtosis
(p = 0.008 for time to
local tumor spread and
p = 0.017 for systemic
progression).

CT imaging
phenotypes and
genetic and
biological
characteristics
PDAC

Iwatate
et al.
[9]

Segmentation
Process
(Number of
Readers)

Genetic
information

Manual (2)

Chang-Gung
Image Texture
Analysis

KRAS, SMAD4,
TP53, and
CDKN2A mutation
status

Semiautomatic (3,
gradient based,
PET-Edge,
MIM)

Unknown

Predicting the ALT
phenotype in
PNET patients

Pyradiomics

Manual (2)

107

116 + 60

121

4. Limitations and Future Directions
While quantitative imaging approaches with radiomics and deep learning show
promise in assisting and improving a range of clinical applications for combating pancreatic
cancer, they do have several limitations.
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One limitation is the inherent uncertainty and heterogeneity in image acquisition. As
these quantitative imaging methods aim at identifying tumor- or lesion-specific characteristics among different patients, variations in image acquisition among patients, such as
differences in makes and models of scanners or in acquisition protocols and reconstruction
parameters, can act as confounding factors. The acquisition hardware, software, procedures, operators, and measurement methods may all contribute to these variabilities. In
addition to image acquisition uncertainty common to other diseases, for pancreatic cancer
respiration-related motion uncertainty needs to be considered, as pancreatic tumors can
undergo considerable motion correlated with breathing. Using 4D or breath-hold CTs, or excluding features sensitive to these motions, may be necessary for the workflow [126]. Thus
far, studies have been conducted to assess these sources of uncertainties and their impacts
and to develop mitigation strategies, although more such studies are needed [91,127]. The
best way to mitigate image acquisition-related uncertainty is to design prospective trials
that use uniform acquisition and reconstruction parameters with a single scanner. This
needs to be a conscious effort on the part of the entire clinical and research community, and
imaging acquisition should be an integral part of standardization for future clinical trials.
For retrospective datasets with heterogeneous image acquisition, mitigation strategies
include applying voxel, gray-level, and bit-depth resampling, applying smoothing filters,
and using test–retest datasets and other uncertainty study findings to exclude features
sensitive or unstable to these variabilities.
Image processing is a necessary step in the quantitative imaging workflow. Lack or
improper execution of processing steps can lead to the degradation of the subsequent radiomic or deep learning models under development. Image resampling and normalization
are important processing steps, and should be optimized for the clinical and modeling
task at hand as well as for the images being used. For example, CT image intensities tend
to be more stable across different scanners and scanning protocols due to the common
Hounsfield Unit definition, whereas MR image intensities are much more variable even
for the same type of image sequences. Applying field bias correction and appropriate normalization is therefore essential for MR-based studies. Currently, there is a need for more
investigations to assess the impact of and optimize image processing for both radiomics
and deep learning applications.
For radiomics modeling, ROI segmentation as an upper-stream step of the workflow adds additional uncertainty due to inter-observer and intra-observer variations. For
segmentation variabilities, having multiple observers and repeated segmentations may
help reduce the segmentation-related uncertainty, as does employing automatic or semiautomatic segmentation. It is important to note that although the above-mentioned uncertainty sources exist for all radiomics and deep learning applications, their effects may
vary for different diseases and clinical applications. For pancreatic cancer, segmentation
uncertainty may play a greater role in the overall uncertainty than for diseases such as
lung cancer where the tumor can be far more easily and accurately delineated. In addition
to assessing the effects of inter-observer segmentation variation on pancreatic cancer radiomics, Wong et al. identified an interdisciplinary variation between radiation oncology
and radiology, possibly attributable to discipline-specific training differences [128]. On
the other hand, Yamashita et al. found in their study that variations in CT scans affected
radiomics reproducibility to a greater extent than segmentation variation [129]. Automatic
or semi-automatic segmentation helps to improve both the consistency and efficiency of
ROI segmentation. However, developing effective and accurate automatic segmentation
methods is particularly challenging for pancreatic cancer as the lesion and its abdominal
background can both appear heterogeneous and similar in intensity on images. Therefore,
algorithms that have found good success for cancers such as lung and liver cancer are
unable to achieve similar segmentation accuracy for pancreatic cancer. Thus far, the utilization of automatic or semi-automatic segmentation has been largely limited to PET-based
quantitative imaging studies, as in that situation the volumes can be more easily defined via
thresholding based on uptake values rather than on anatomy. In more recent years, there
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has been progress in both normal and cancerous pancreatic auto-segmentation algorithms,
especially with the help of deep learning [130].
For deep learning studies, one limitation is a lack of interpretability and transparency.
Avanzo et al. suggests that machine learning and deep learning are less intuitive than radiomics models alone [10]. Manually-crafted radiomic features are attributable to physical
properties, and partially resemble the qualitative and descriptive image features conventionally used by human experts. On the other hand, deep features are often something of a
black box. One continuing effort of deep learning studies is to improve the explainability
and transparency of the models. Strategies such as dimension reduction, feature importance, attention mechanisms, knowledge distillation, and surrogate models have been
developed, although further work is needed [131]. New fusion models incorporating the
intuitiveness of radiomic features with the accuracy of deep learning models are becoming
increasingly popular, and show promise in predictive accuracy; however, their use remains
limited. Overall, more studies focusing on pancreatic diseases with these quantitative
imaging approaches are warranted in order to provide further evidence supporting their
clinical promise.
Aside from these general limitations and challenges of quantitative imaging methods,
pancreatic cancer presents several major challenges of its own, chiefly the limited dataset
size for such studies. The reason is twofold: first, the prognosis of pancreatic cancer is
very poor and patients deteriorate rapidly; second, pancreatic cancer has a relatively low
incidence compared with other major cancers. Therefore, there are usually limited available
patient populations at a given institution, and single-institutional studies, which make up
most of the existing research, are often conducted on relatively small groups of patients
compared to other cancers. Due to these limitations, the accuracy and predictive power of
radiomics and deep learning for pancreatic cancer are relatively low.
Another limitation is the lack of standardization in study design and analysis workflow
across different studies, often making the quantitative findings from individual studies
difficult to compare against one another. Most existing studies are retrospective studies and
many have small patient populations. For these studies with smaller sample sizes, model
overfitting tends to be an issue if the study is not carefully and rigorously designed, leading
to the inflating of model performance in studies which can be difficult to reproduce or
generalize. Due to variation in the rigor and design of studies, a higher AUC reported in one
study may not represent a superior model to one with a lower AUC reported for the same
clinical application by another study. To this end, Gillies et al. suggest that establishing
benchmarks for the conduct of radiomic studies could help to solve the challenge of
reproducibility [132]. In addition, the Radiomics Quality Score (RQS), established in 2017
by Lambin et al., could help with the uncertainties associated with performing radiomic
studies [133]. The RQS is a 36-point scale that either rewards or penalizes studies based on
their methodology, analysis, and reporting with the ultimate purpose of encouraging the
best scientific practices and helping to standardize the radiomic workflow [133]. The use of
the RQS could help to promote standardization within the radiomic field and make the
quantitative results from different studies more comparable.
As many fields of cancer research have adopted the use of computer-aided diagnosis
and prediction models, these are desperately needed within the clinical realm of pancreatic
cancer in order to push back against this vicious disease. While these studies show promise
for “phenotyping” tumors and pancreatic disease prognosis, continued research is needed
to resolve the issue of unresectable pancreatic cancer prognosis [134]. While radiomics and
deep learning models have shown promise for the diagnosis, prognosis, and prediction of
optimal treatment of pancreatic diseases, there is a need for further and better studies. Both
radiomics and deep learning approaches rely on large sample sizes and high-quality data.
Prospective studies with standardized and optimized image acquisition and processing
remain highly desirable. There is a need for normalization within the radiomics and deep
learning workflow as well, in order to reduce uncertainties, increase reproducibility, and
benchmark results across different studies. Requiring studies to make their data and

Cancers 2022, 14, 1654

27 of 33

algorithms publicly available can help to increase the resulting transparency of a study
and increase data availability for future studies. As these methods demonstrate the great
potential of imaging data science in combating pancreatic cancer, continuing efforts need to
be made to increase the interpretability and generalizability of the models and to promote
clinical confidence and trust.
5. Conclusions
In this review, we have discussed the use of radiomics and deep learning as regards
pancreatic cancer. Starting with a clinical introduction to pancreatic cancer and technical
overviews of these two quantitative imaging analysis methods, clinical applications were
reviewed for precancerous lesion diagnosis, pancreatic cancer detection and diagnosis,
prognosis prediction, treatment stratification, and radiogenomics. The limitations of the
current models and approaches were discussed along with possible solutions and potential
future directions. Despite the discussed limitations, there is clear evidence of the promise
of radiomics and deep learning models in the clinical workplace. This review provides
a comprehensive literature summary and discussion for both researchers and clinicians
interested in radiomics and deep learning applications in pancreatic cancer.
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Alternative Lengthening of Telomeres (ALT); Artificial Neural Network (ANN); Atypical Serous Cystadenomas (ASCN); Area Under Curve (AUC); Branch-Ductal Intraductal
Papillary Mucinous Neoplasm (BD-IPMN); Computer-Aided Diagnosis (CAD); Concordance Index (CI); Convolutional Neural Network (CNN); Chemoradiation Therapy (CRT);
Fluorine 18-fluorodeoxyglucose (FDG); Generative Adversarial Network (GAN); GrayLevel Co-occurrence Matrix (GLCM); Gray-Level Run-Length Matrix (GLRLM); Intraductal
Papillary Mucinous Neoplasm (IPMN); Least Absolute Shrinkage and Selection Operator
(LASSO); Macrocystic Serous Cystadenoma (MaSCA); Mucinous Cystadenomas (MCA);
Mucinous Cystic Neoplasm (MCN); Mean CT Number (MCTN); Mass-forming Chronic
Pancreatitis (MFCP); Machine Learning (ML); Multilayer Perceptron (MLP); Multi-channelMulticlassifier-Random Forest (MMRF); Minimum Redundancy and Maximum Relevancy
(mRMR); Pancreatic Cystic Lesion (PCL); Pancreatic Cystic Neoplasm (PCN); Pancreatic
Adenocarcinoma (PDAC); Neuroendocrine Tumor (NET) or Pancreatic Neuroendocrine
Tumor (PNET); Pancreatic Intraepithelial Neoplasia (PanIN); Pancreatic Neuroendocrine
Neoplasm (PanNEN); Region of Interest (ROI); Radiomics Quality Score (RQS); Serous
Cystadenomas (SCA); Serous Cystic Neoplasm (SCN); Standard Deviation (SD); Solid Pseudopapillary Neoplasm (SPN); Standardized Uptake Value (SUV); Volume of Interest (VOI).
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